Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31742325 | 1.00 | EPHX2 (0.38) | EPHX2GPR88MEN1KMT2AACKR3 | |
| SCHEMBL5677229 | 0.87 | GPR88 (0.45) | EPHX2GPR88MEN1KMT2AACKR3 | |
| SCHEMBL31742335 | 0.82 | EPHX2 (0.37) | EPHX2GPR88ACKR3HTR2AMCL1 | |
| SCHEMBL31742326 | 0.82 | EPHX2 (0.37) | EPHX2GPR88ACKR3HTR2AMCL1 | |
| SCHEMBL16585394 | 0.82 | HTR2A (0.39) | EPHX2GPR88ACKR3HTR2AHTR2C | |
| SCHEMBL16585393 | 0.82 | HTR2A (0.39) | EPHX2GPR88ACKR3HTR2AHTR2C | |
| SCHEMBL22654407 | 0.80 | KDM1A (0.48) | EPHX2GPR88MEN1KMT2AMCL1 | |
| SCHEMBL5683647 | 0.78 | EPHX2 (0.52) | EPHX2GPR88MCL1 | |
| SCHEMBL15254908 | 0.78 | EPHX2 (0.52) | EPHX2GPR88MCL1 | |
| SCHEMBL15254635 | 0.78 | EPHX2 (0.52) | EPHX2GPR88MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163766-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7872009-B2 | Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118250-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | EPHX2 590/4885GPR88 1263/4885MEN1 3013/4885 |
| US-20070185103-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | EPHX2 590/4885GPR88 1263/4885MEN1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.